Pascal Bonnet
Professeur de Chimie ; Vice-Président de la Recherche de l'Université d'Orléans
48
Documents
Affiliations actuelles
- 199928
- 300297
Identifiants chercheurs
- pascal-bonnet
- 0000-0001-6485-138X
- ResearcherId : C-7273-2015
- ResearcherId : F-7887-2011
- IdRef : 069441405
- VIAF : 197041422
- ISNI : 000000041917668X
Publications
- 44
- 1
- 1
- 1
- 8
- 3
- 1
- 1
- 1
- 1
|
PrePeP – A Tool for the Identification and Characterization of Pan Assay Interference Compounds24th ACM SIGKDD International Conference on Knowledge Discovery & Data Mining, Aug 2018, Londres, United Kingdom. pp.462-471, ⟨10.1145/3219819.3219849⟩
Communication dans un congrès
hal-01939468v1
|
Développement de petites molécules inhibitrices des LIM kinases, nouvelles cibles thérapeutiques pour lutter contre le cancer, les maladies neurologiques et la neurofibromatoseJournée Fédération CBM-ICOA, Jan 2018, Orléans, France
Communication dans un congrès
hal-02928530v1
|
|
Conception of DYRK1A kinase inhibitors via metal-catalyzed C-H arylation, inspired by fragment-growing studiesInternational Electronic Conference on Medicinal Chemistry (ECMC, 4, 2018), Jean-Jacques Vanden Eynde (coord.), Nov 2018, [online], Belgium. ⟨10.3390/ecmc-4-05580⟩
Communication dans un congrès
hal-02383907v1
|
|
Fragment covalent docking (FCD) approach: An innovative in silico tools for the prediction of peptide-protein interaction256th National Meeting and Exposition of the American-Chemical-Society Nanoscience, Nanotechnology and Beyond (ACS), American Chemical Society (ACS). USA., Aug 2018, Boston, United States. pp.2
Communication dans un congrès
hal-02734800v1
|
|
Neurofibromatosis type I: from basic to applied research4th LIA Workshop, Jun 2017, Cracovie, Poland
Communication dans un congrès
hal-02928517v1
|
Development of small molecule inhibitors of LIM kinases, new therapeutic targets to treat Neurofibromatosis type IJoint Global Neurofibromatosis Conference 2018, Nov 2018, Paris, France
Poster de conférence
hal-02924077v1
|
|
LIM Kinases: new anticancer therapeutic targetsBreast Cancer Symposium, Jun 2017, Nantes, France
Poster de conférence
hal-03680148v1
|
|
LIM kinases: new therapeutic targets to treat Neurofibromatosis type IPoster de conférence hal-02453490v1 |
|
Computational study of ligand-receptor binding process using enhanced molecular dynamics simulations21st European Symposium on Quantitative Structure-Activity Relationship, Sep 2016, Vérone, Italy
Poster de conférence
hal-02919149v1
|
|
Projet Région LiCorNe: LIMK protein inhibitors, new therapeutic agents for treatment of cognitive disorders associated with type I NeurofibromatosisJournée Fédération PCV FR2708, Jan 2016, Orléans, France
Poster de conférence
hal-02924056v1
|
4-(7H-Pyrrolo[2,3-D]pyrimidin-4-yl)-3,6-dihydropyridine-(2H)-carboxamide derivatives as Limk and/or Rock kinases inhibitors for use in the treatment of cancerFrance, Patent n° : WO2021239727 A1. BCT. 2021
Brevet
hal-03555349v1
|